Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

被引：0

作者：

Gabe S. Sonke

Lowell L. Hart

Mario Campone

Frans Erdkamp

Wolfgang Janni

Sunil Verma

Cristian Villanueva

Erik Jakobsen

Emilio Alba

Erik Wist

Anne M. Favret

Thomas Bachelot

Roberto Hegg

Paul Wheatley-Price

Farida Souami

Santosh Sutradhar

Michelle Miller

Caroline Germa

Howard A. Burris

机构：

[1] Netherlands Cancer Institute/BOOG Study Center,Department of Medical Oncology

[2] Florida Cancer Specialists,Zuyderland Medical Center

[3] Sarah Cannon Research Institute,University Hospital of Besançon

[4] Institut de Cancérologie de l’Ouest – René Gauducheau Centre de Recherche en Cancérologie,Virginia Cancer Specialists PC

[5] Sittard-Geleen/Heerlen,Ottawa Hospital Research Institute

[6] Universitätsklinikum Ulm,undefined

[7] Tom Baker Cancer Centre,undefined

[8] Hospital Jean-Minjoz,undefined

[9] Lillebælt Hospital,undefined

[10] Hospital Universitario Virgen de la Victoria,undefined

[11] IBIMA,undefined

[12] Oslo University Hospital,undefined

[13] US Oncology,undefined

[14] Centre Léon Bérard,undefined

[15] Hospital Pérola Byington Centro de Referência da Saúde da Mulher,undefined

[16] University of Ottawa,undefined

[17] Novartis Pharma AG,undefined

[18] Novartis Pharmaceuticals Corporation,undefined

来源：

Breast Cancer Research and Treatment | 2018年 / 167卷

关键词：

Breast cancer; CDK inhibitor; Ribociclib; Endocrine therapy; Elderly; Hormone receptor-positive;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：659 / 669

页数：10

共 50 条

[21] Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
Yardley, Denise A.
Hart, Lowell
Favret, Anne
Blau, Sibel
Diab, Sami
Richards, Donald
Sparano, Joseph
Beck, J. Thad
Richards, Paul
Ward, Patrick
Ramaswamy, Bhuvaneswari
Tsai, Michaela
Blackwell, Kimberly
Pluard, Timothy
Tolaney, Sara M.
Esteva, Francisco J.
Truica, Cristina, I
Alemany, Carlos
Volas-Redd, Gena
Shtivelband, Mikhail
Purkayastha, Das
Dalal, Anand A.
Miller, Michelle
Hortobagyi, Gabriel N.
CLINICAL BREAST CANCER, 2019, 19 (04) : 268 - +
[22] Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy
Villacampa, Guillermo
Pare, Laia
Hernando, Cristina
Arumi, Miriam
Munoz, Montserrat
Gil-Gil, Miguel
Izarzugaza, Yann
Ferrer, Neus
Montano, Alvaro
Ciruelos, Eva
Gonzalez-Santiago, Santiago
Falato, Claudette
Villagrasa, Patricia
Gavila, Joaquin
Prat, Aleix
Pascual, Tomas
CANCER RESEARCH, 2022, 82 (04)
[23] Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
Liu, Qi
Hou, Lingli
Zhao, Ying
Yang, Hongwei
Mo, Zhengying
Yu, Fei
CLINICS, 2023, 78
[24] Thromboembolic events (TEE) in patients with HER2-negative, hormone receptor-positive metastatic breast cancer treated with Ribociclib combined with Letrozole or Fulvestrant. Real-world data
Abdel-Razeq, Hikmat
Tamimi, Faris
Edaily, Sarah
Sharaf, Baha'
Abunasser, Mahmoud
Salama, Osama
Abdel-Razeq, Rashid
Abdulelah, Hazem
Bater, Rayan
CANCER RESEARCH, 2022, 82 (04)
[25] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
Cardoso, Fatima
Hirshfield, Kim M.
Kraynyak, Kimberly A.
Tryfonidis, Konstantinos
Bardia, Aditya
NPJ BREAST CANCER, 2024, 10 (01)
[26] Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
Sunil Verma
Joyce O’Shaughnessy
Howard A. Burris
Mario Campone
Emilio Alba
David Chandiwana
Anand A. Dalal
Santosh Sutradhar
Mauricio Monaco
Wolfgang Janni
Breast Cancer Research and Treatment, 2018, 170 : 535 - 545
[27] Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
Howard A. Burris
Arlene Chan
Aditya Bardia
J. Thaddeus Beck
Joohyuk Sohn
Patrick Neven
Debu Tripathy
Seock-Ah Im
Stephen Chia
Francisco J. Esteva
Lowell Hart
Juan Pablo Zarate
Antonia Ridolfi
Karen Rodriguez Lorenc
Denise A. Yardley
British Journal of Cancer, 2021, 125 : 679 - 686
[28] Efficacy and safety of ribociclib plus letrozole in US patients enrolled in the MONALEESA-2 study
Yardley, Denise A.
Hart, Lowell
Favret, Anne
Blau, Sibel
Diab, Sami
Richards, Donald
Sparano, Joseph
Beck, J. Thad
Richards, Paul
Ward, Patrick
Ramaswamy, Bhuvaneswari
Tsai, Michaela
Pluard, Timothy
Tolaney, Sara
Esteva, Francisco
Small, Tania
Purkayastha, Das
Miller, Michelle
Hortobagyi, Gabriel
CANCER RESEARCH, 2018, 78 (04)
[29] Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Prat, Aleix
Saura, Cristina
Pascual, Tomas
Hernando, Cristina
Munoz, Montserrat
Pare, Laia
Gonzalez Farre, Blanca
Fernandez, Pedro L.
Galvan, Patricia
Chic, Nuria
Gonzalez Farre, Xavier
Oliveira, Mafalda
Gil-Gil, Miguel
Arumi, Miriam
Ferrer, Neus
Montano, Alvaro
Izarzugaza, Yann
Llombart-Cussac, Antonio
Bratos, Raquel
Gonzalez Santiago, Santiago
Martinez, Eduardo
Hoyos, Sergio
Rojas, Beatriz
Antonio Virizuela, Juan
Ortega, Vanesa
Lopez, Rafael
Celiz, Pamela
Ciruelos, Eva
Villagrasa, Patricia
Gavila, Joaquin
LANCET ONCOLOGY, 2020, 21 (01): : 33 - 43
[30] A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Vaklavas, Christos
Stringer-Reasor, Erica M.
Elkhanany, Ahmed M.
Ryan, Kevin J.
Li, Yufeng
Theuer, Charles P.
Acosta, Edward P.
Wei, Shi
Yang, Eddy S. S.
Grizzle, William E.
Forero-Torres, Andres
BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (02) : 217 - 229

← 1 2 3 4 5 →